InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #AI--InterVenn Biosciences today announced it has raised $34M in a Series B fundraising. The latest round was led by Anzu Partners with full participation of Genoa Ventures, Amplify Partners, and True Ventures; Xeraya Capital and the Ojjeh Family joined the syndicate as well. Funds will be used to commercialize the company’s High-Throughput-Glycoproteomic powered diagnostic for ovarian cancer; to service increasing partnership platform demand; and to acc

Click to view original post